Mitarbeiter: 12 (2023.0)Rechtsform: SCA (commandite par actions)Größe: GEGründungsdatum: 2017-11-07 (8 Jahre)Status: AktivBranche: Analyses, essais et inspections techniquesStandort: NANTES (44300), Loire-Atlantique
EUROFINS BIOLOGIE MOLECULAIRE FRANCE : revenue, balance sheet and financial ratios
EUROFINS BIOLOGIE MOLECULAIRE FRANCE is a French company
founded 8 years ago,
specialized in the sector Analyses, essais et inspections techniques.
Based in NANTES (44300),
this company of category GE
shows in 2024 a revenue of 6.9 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Historique financier - EUROFINS BIOLOGIE MOLECULAIRE FRANCE (SIREN 833458730)
Kennzahl
2024
2023
2022
2020
2019
2018
2017
Umsatz
6 929 329 €
6 489 424 €
6 803 617 €
6 626 070 €
5 415 939 €
N/C
N/C
Nettoergebnis
157 558 €
-89 633 €
-102 450 €
-54 085 €
-12 365 €
76 822 €
-1 300 €
EBITDA
275 025 €
-176 281 €
-274 481 €
53 805 €
383 700 €
-1 287 181 €
-1 300 €
Nettomarge
2.3%
-1.4%
-1.5%
-0.8%
-0.2%
N/C
N/C
Umsatz und Gewinn- und Verlustrechnung
In 2024, EUROFINS BIOLOGIE MOLECULAIRE FRANCE achieves revenue of 6.9 M€. Over the period 2019-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +5.1%. Vs 2023: +7%. After deducting consumption (1.1 M€), gross margin stands at 5.8 M€, i.e. a rate of 84%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 275 k€, representing 4.0% of revenue. Positive scissor effect: EBITDA margin improves by +6.7 pts, sign of improved operational efficiency. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 158 k€, i.e. 2.3% of revenue. This profit can be retained or distributed to shareholders.
Umsatz (2024)
?
Umsatz
Definition
Gesamtbetrag der Verkäufe von Waren und Dienstleistungen des Unternehmens.
Formel
Warenverkäufe + Verkaufte Produktion
6 929 329 €
Bruttomarge (2024)
?
Bruttomarge
Definition
Differenz zwischen Umsatz und Wareneinsatz.
Formel
Umsatz - Wareneinsatz
5 805 012 €
EBITDA (2024)
?
EBITDA (Betriebsergebnis vor Abschreibungen)
Definition
Ressource générée par l'activité courante, avant amortissements et charges financières.
Formel
Wertschöpfung - Personalkosten - Steuern
Interpretation
Positiv = rentable Tätigkeit
275 025 €
EBIT (2024)
?
EBIT (Betriebsergebnis)
Definition
Betriebsergebnis, einschließlich Abschreibungen und Rückstellungen.
Formel
EBITDA - Abschreibungen und Rückstellungen + Auflösungen
175 408 €
Nettoergebnis (2024)
?
Nettoergebnis
Definition
Bénéfice ou perte après toutes les charges, y compris impôts et éléments exceptionnels.
Le compte de résultat détaillé n'est pas disponible pour cette entreprise (liasse simplifiée ou données confidentielles).
Évolution graphique
Anzeigen :
Visualisierung erstellt mit numbers.finance Sources : INPI & BCE - Anpassungen : Ministère de l'Économie
Aktiva
Chargement des données...
Poste
Brutto
Abschr.
Netto
%
Entwicklung
Données de bilan actif non disponibles pour cette entreprise
Passiva
Chargement des données...
Poste
Jahr
%
Entwicklung
Données de bilan passif non disponibles pour cette entreprise
Solvenz- und Verschuldungskennzahlen
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 55%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 1.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
Verschuldungsgrad (2024)
?
Verschuldungsgrad
Definition
Misst das Verhältnis von Schulden zu Eigenkapital.
Formel
(Finanzschulden / Eigenkapital) x 100
Interpretation
< 50% : Faible 50-100% : Moderat > 100% : Hoch
0.013%
Finanzielle Autonomie (2024)
?
Finanzielle Autonomie
Definition
Anteil des Eigenkapitals an der Gesamtfinanzierung.
Entwicklung der Solvenzkennzahlen EUROFINS BIOLOGIE MOLECULAIRE FRANCE
Visualisierung erstellt mit numbers.finance Sources : INPI & BCE - Anpassungen : Ministère de l'Économie
Kennzahl
2017
2018
2019
2020
2022
2023
2024
Verschuldungsgrad
0.0
0.0
0.0
0.0
0.003
6.678
0.013
Finanzielle Autonomie
74.0
19.18
51.904
41.974
46.489
45.501
54.556
Rückzahlungsfähigkeit
0.0
0.0
0.0
0.0
0.0
-0.32
0.002
Cashflow / Umsatz
None%
None%
-0.751%
-2.401%
-6.607%
-4.815%
1.616%
Positionnement sectoriel
Debt ratio
0.012024
2022
2023
2024
Q1: 0.0
Méd: 9.99
Q3: 48.5
Excellent
In 2024, the debt ratio of EUROFINS BIOLOGIE MOLECUL... (0.01) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
54.56%2024
2022
2023
2024
Q1: 11.63%
Méd: 34.78%
Q3: 58.76%
Good+9 pts über 3 Jahre
In 2024, the financial autonomy of EUROFINS BIOLOGIE MOLECUL... (54.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
0.0 years2024
2022
2023
2024
Q1: 0.0 years
Méd: 0.0 years
Q3: 0.87 years
Good+25 pts über 3 Jahre
In 2024, the repayment capacity of EUROFINS BIOLOGIE MOLECUL... (0.00) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquiditätskennzahlen
The liquidity ratio (= Current assets / Current liabilities) stands at 168.54. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 2.2x. Financial charges are adequately covered by operations.
Liquiditätsquote (2024)
?
Liquiditätsquote
Definition
Fähigkeit, kurzfristige Schulden mit dem Umlaufvermögen zu decken.
Formel
Umlaufvermögen / Kurzfristige Verbindlichkeiten
Interpretation
> 1.5 : Sehr gut 1-1.5 : Angemessen < 1 : Risque de liquidité
168.537
Zinsdeckung (2024)
?
Zinsdeckung
Definition
Fähigkeit, Zinsaufwendungen mit dem Betriebsergebnis zu decken.
Entwicklung der Liquiditätskennzahlen EUROFINS BIOLOGIE MOLECULAIRE FRANCE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Kennzahl
2017
2018
2019
2020
2022
2023
2024
Liquiditätsquote
384.615
134.064
173.387
140.271
141.717
137.541
168.537
Zinsdeckung
0.0
-0.189
1.394
2.842
-0.444
-4.674
2.191
Positionnement sectoriel
Liquidity ratio
168.542024
2022
2023
2024
Q1: 133.14
Méd: 205.95
Q3: 337.03
Average+11 pts über 3 Jahre
In 2024, the liquidity ratio of EUROFINS BIOLOGIE MOLECUL... (168.54) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
2.19x2024
2022
2023
2024
Q1: 0.0x
Méd: 0.02x
Q3: 2.48x
Good+47 pts über 3 Jahre
In 2024, the interest coverage of EUROFINS BIOLOGIE MOLECUL... (2.2x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Umlaufvermögensbedarf und Zahlungsfristen
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 48 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 41 days. The company must finance 7 days of gap between collections and payments. Inventory turnover is 23 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 83 days of revenue, i.e. 1.6 M€ to permanently finance.
Operatives Working Capital (2024)
?
Operatives Working Capital
Definition
Besoin de financement généré par le cycle d'exploitation (stocks + créances - dettes fournisseurs).
(Lieferantenverbindlichkeiten / Einkäufe inkl. MwSt.) x 360
Interpretation
Je länger die Frist, desto besser für die Liquidität
41 j
Lagerumschlag (2024)
?
Lagerumschlag (Tage)
Definition
Durchschnittliche Lagerdauer für Waren oder Materialien.
Formel
(Vorräte / Einkaufskosten) x 360
Interpretation
Je niedriger das Verhältnis, desto schneller der Umschlag
23 j
Working Capital in Umsatztagen (2024)
?
Working Capital in Umsatztagen
Definition
Drückt den Betriebskapitalbedarf in Umsatztagen aus.
Formel
(BFR exploitation / CA) x 360
Interpretation
Je weniger Tage, desto besser das Working Capital Management
83 j
Entwicklung des Working Capital und der Zahlungsfristen EUROFINS BIOLOGIE MOLECULAIRE FRANCE
Visualisierung erstellt mit numbers.finance Sources : INPI & BCE - Anpassungen : Ministère de l'Économie
Kennzahl
2017
2018
2019
2020
2022
2023
2024
BFR d'exploitation
0 €
0 €
1 931 432 €
2 121 999 €
1 762 341 €
1 639 553 €
1 599 151 €
Lagerumschlag (Tage)
0
0
23
47
26
26
23
Crédit clients (jours)
0
0
34
44
65
60
48
Crédit fournisseurs (jours)
300
54
73
83
56
59
41
Positionnement de EUROFINS BIOLOGIE MOLECULAIRE FRANCE dans son secteur
Vergleich mit der Branche Analyses, essais et inspections techniques
Bewertungsschätzung
Indicative estimate only : the number of comparable transactions in this sector is limited (41 transactions).
This range of 284 141€ to 2 313 696€ is provided for information purposes only and requires in-depth analysis to be confirmed.
Estimated enterprise value2024
Indicative
284k€1384k€2313k€
1 384 593 €Range: 284 141€ - 2 313 696€
NAF 5 année 2024
Bewertungsentwicklung
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 41 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Analyses, essais et inspections techniques)
Compare EUROFINS BIOLOGIE MOLECULAIRE FRANCE with other companies in the same sector:
Frequently asked questions about EUROFINS BIOLOGIE MOLECULAIRE FRANCE
What is the revenue of EUROFINS BIOLOGIE MOLECULAIRE FRANCE ?
The revenue of EUROFINS BIOLOGIE MOLECULAIRE FRANCE in 2024 is 6.9 M€.
Is EUROFINS BIOLOGIE MOLECULAIRE FRANCE profitable?
Yes, EUROFINS BIOLOGIE MOLECULAIRE FRANCE generated a net profit of 158 k€ in 2024.
Where is the headquarters of EUROFINS BIOLOGIE MOLECULAIRE FRANCE ?
The headquarters of EUROFINS BIOLOGIE MOLECULAIRE FRANCE is located in NANTES (44300), in the department Loire-Atlantique.
Where to find the tax return of EUROFINS BIOLOGIE MOLECULAIRE FRANCE ?
The tax return of EUROFINS BIOLOGIE MOLECULAIRE FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EUROFINS BIOLOGIE MOLECULAIRE FRANCE operate?
EUROFINS BIOLOGIE MOLECULAIRE FRANCE operates in the sector Analyses, essais et inspections techniques (NAF code 71.20B). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Drehen Sie Ihr Telefon ins Querformat, um das Diagramm anzuzeigen